Outcomes of comparing S-1 plus cisplatin with Gemcitabine plus cisplatin for non-small-cell lung cancer

Objective To evaluate the efficacy and toxicity of treatment with cisplatin plus S-1 versus that with cisplatin plusGemcitabine in patients with advanced non-small-cell lung cancer ( NSCLC) . Methods A total of 95 NSCLC patients of stage IIIB-IV were divided into two groups: 44 cases were assigned to Group A,treated with cisplatin plus S-1,and 51 were assigned to Group Brecived cisplatin plus Gemcitabine. Results In Group A and Group B,the remission rate ( CR + PR) were 22. 7% and 25. 5% ( P= 0. 15) ,the disease control rate ( CR + PR + SD) were 72. 7% and 74. 5% ( P = 0. 32) . The 1-year survival rate were 53. 5% and51. 9% ,respectively. The median PFS were 5. 3 months ( 95% CI,5. 091 ～ 5. 509) and 4. 8 months( 95% CI,4. 656 ～ 4. 944) ,whichwere similar in both treatment groups ( Log-rank P = 0. 513) . There were more oral mucositis and neuropathy and less myelosuppres-sion were founded in Group A compared with Group B. Conclusion This chemotherapy regimen with cisplatin plus S-1 is a promis-ing treatment for advanced NSCLC because of its high response rates,good survival rates,and mild toxicities.